Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans BC01
- Development stage
- Preclinical
- Lead developer
- Thankcome Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans BC01 is a specific, proprietary strain of the spore-forming probiotic bacterium *Bacillus coagulans*. [3] It is being developed by Thankcome Biological Science and Technology (Suzhou) Co., Ltd. for its potential therapeutic effects. [3, 9] The strain is noted for its high stability against heat and acid, which allows it to survive passage through the stomach and reach the intestines. [3, 18] Clinical and preclinical studies are evaluating its efficacy in managing functional constipation. [1, 2, 6] The proposed mechanism involves modulating the gut microbiota, regulating gastrointestinal motility, increasing short-chain fatty acid (SCFA) production, and reducing intestinal inflammation. [1, 2, 6] It is also used as a food-grade ingredient in various products. [4, 9]
- Other names
- 凝结芽孢杆菌BC01Weizmannia coagulans BC01
Beyond the preview
Go deeper on bacillus coagulans BC01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans BC01.